Artificial intelligence in healthcare sits at the crossroads of two forces investors are watching closely today: inflation sensitive policy shifts and fast moving technology that aims to cut costs and improve outcomes. While central banks weigh interest rate decisions and hospitals face pressure to do more with less, AI driven tools are being applied to diagnostics, treatment decisions, and day to day clinical workflows. The Transformative AI Healthcare Stocks screener focuses on companies directly exposed to this trend. In this article, you will see 3 of the strongest stocks highlighted from that screener for further research.

Butterfly Network (BFLY)

Overview: Butterfly Network is a medical imaging company that makes handheld ultrasound devices, such as its Butterfly iQ+ and iQ3 probes, that connect to smartphones, tablets, and hospital systems, using software and AI to bring whole body imaging to more clinicians at the bedside. It also offers enterprise tools like Compass AI and ScanLab, plus veterinary and bladder focused products, and sells through a mix of direct sales, distributors, and online channels in the United States and internationally.

Operations: Butterfly Network generates about US$102.9m in revenue from its AI enhanced personal ultrasound solution, with roughly US$81.8m from the United States and US$21.2m from international markets.

Market Cap: US$2.07b

Butterfly Network gives you exposure to handheld ultrasound hardware tightly linked with AI software at a time when hospitals are under pressure to do more with fewer resources. Its ultrasound on chip technology now sits at the heart of a multi year licensing and co development agreement with Midjourney worth up to US$74m over five years. Revenue is forecast to grow strongly, earnings are expected to move toward profitability, and recent deals in Brazil and neuroimaging partnerships show the tech being used in real world settings. Investors also need to weigh a still loss making business, a high P/S multiple, share price volatility, and recent insider selling. The bigger question is how all of these moving parts fit together for Butterfly Network’s long term potential in AI powered imaging.

Butterfly Network’s ultrasound on chip story is accelerating, but the real tension sits between high growth expectations, ongoing losses, and insider sales. Get the fuller picture with the 1 key reward and 2 important warning signs (1 is major!)

Pfizer (PFE)

Overview: Pfizer is a large global biopharmaceutical company that discovers, develops, manufactures, and sells prescription medicines and vaccines across areas such as cardiovascular disease, migraine, inflammation and immunology, rare diseases, infectious disease, and oncology, supported by partnerships and AI driven drug discovery collaborations.

Operations: Pfizer generates about US$63.2b in revenue from its Global Biopharmaceuticals Business and segment adjustments, with US$37.4b from the United States, US$9.4b from emerging markets, and US$16.4b from other developed markets.

Market Cap: US$136.1b

Pfizer gives you exposure to a broad portfolio of branded drugs, vaccines, and biosimilars at a time when obesity, oncology, and rare disease treatments are a key focus for healthcare systems worldwide, and it is leaning into AI collaborations to speed up antibody and drug design. The picture is not straightforward, with revenue and earnings expected to decline over the next few years, a dividend yield above 7% that is not well covered by earnings or free cash flow, and a history of large one off losses that make recent results harder to interpret. For investors willing to accept these trade offs, the combination of a sizeable late stage pipeline, an emerging markets growth focus, and a valuation that is at a discount relative to some peers may make Pfizer a stock that warrants closer attention for AI enabled healthcare exposure.

Pfizer’s late stage pipeline and its AI drug design initiatives can be easy to overlook when attention centers on falling earnings and a high headline yield. Consider these factors together with the 1 key reward and 4 important warning signs (3 are major!)

Medtronic (MDT)

Overview: Medtronic is a large medical device company that provides therapies across cardiovascular care, brain and spine disorders, surgical care, and diabetes management, supplying hospitals and specialists with everything from pacemakers and cardiac ablation systems to surgical robotics, AI powered surgical video tools, neuromodulation implants, and insulin pumps worldwide.

Operations: Medtronic generates about US$36.4b in revenue, with roughly US$14.0b from Cardiovascular, US$10.3b from Neuroscience, US$8.8b from Medical Surgical, and US$3.2b from other activities, plus smaller unallocated adjustments.

Market Cap: US$101.4b

Medtronic gives you exposure to chronic disease demand and AI enabled devices, from cardiac ablation and hypertension systems to the Hugo robotic surgery platform and AI supported spine and neuromodulation tools. Analysts currently expect both earnings and margins to improve. The story is not risk free, however, with margin pressure, several underperforming segments, recalls, and execution risk around new launches and a complex Diabetes spin off. With a long dividend track record, a 3.59% yield, and a P/E below many medical equipment peers, the stock sits in an area that combines elements of both quality and controversy. The key question for investors is how its product cycle and restructuring plans could reshape the balance of growth and risk from this point.

Medtronic’s mix of AI devices, a 3.59% yield, and a P/E below many peers hints at a story the headline numbers do not fully capture yet. Get the full context with the analysis report for Medtronic

The three stocks in this article are only a starting point, and the full Transformative Artificial intelligence (AI) Healthcare Stocks screener has uncovered 36 more companies with equally compelling AI healthcare narratives that you can review through the Transformative Artificial intelligence (AI) Healthcare Stocks screener. Identify, filter, and analyze the specific catalysts and storylines that matter most to you so you can focus on the AI healthcare stocks that best match your highest conviction ideas.

Take Control of Your Investment Journey

If Medtronic or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Curious To Explore Alternative Stock Paths

Fresh ideas tend to move first. By the time momentum appears obvious, the most attractive entry points may have slipped away. Scan these curated stock shortlists before the crowd and consider your options.

• Spot companies quietly building strong finances before headlines catch up by reviewing the curated list of solid balance sheet and fundamentals (47 results).
• Explore potential income and resilience trends by scanning a hand picked mix of high yield stocks in the 7 dividend fortresses.
• Hunt for early stage companies with strong fundamentals that are still flying under most radars using the focused 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.